Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily



Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243
FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.20 0.0500 +33.33%
CNDO $2.41 0.3600 +17.56%
ONTY $1.86 0.1700 +10.06%
NLNK $38.47 3.1900 +9.04%
IDRA $3.00 0.2000 +7.14%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IMNP $2.62 -0.1300 -4.73%
Kite $42.96 -1.2400 -2.81%
ARGS $8.50 -0.2200 -2.52%
MEIP $6.73 -0.1600 -2.32%
SRNE $3.80 -0.0900 -2.31%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

New ASCO Study Aims to Learn from Patient Access to Targeted Cancer Drugs Used Off-Label

(ASCO in Action) Nov 21, 2014 - ASCO plans to launch a first-ever study that will offer cancer patients access to molecularly-targeted cancer drugs and collect “real-world” data on clinical outcomes to help oncologists learn the best uses of these drugs outside of approved indications, ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, reported today at a cancer research conference held in Washington, DC.
read article 



Transposagen Biopharmaceuticals Enters Into Research Collaboration and Worldwide License Agreement With Janssen For Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapies

(Benzinga) Nov 24, 2014 - Transposagen Biopharmaceuticals, Inc., a private biotechnology company headquartered in Lexington, KY, today announced they have entered into a research collaboration and worldwide license agreement with Janssen Biotech, Inc. to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T).
read article 



Juno's Leukemia Drug May Get Speedier FDA Review

(Puget Sound Business Journal blog) Nov 24, 2014 - Juno Therapeutics said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its drug targeting lymphoblastic leukemia.
read article 



Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types

(CNNMoney) Nov 24, 2014 - Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
read article 



Cancer-Risk Debate Didn’t Halt Surgeries

(Wall Street Journal) Nov 23, 2014 - Doctors at a prominent Boston hospital continued to use a surgical tool during hysterectomies for two years after compiling data in 2011 that questioned the safety of the device and discussing its risks, said hospital officials and doctors.
read article (paid subscription required) 



Adult Survivors of Childhood Eye Cancer Experience Few Cognitive or Social Setbacks

(Wiley) Nov 24, 2014 - Adult survivors of retinoblastoma, a type of eye cancer that usually develops in early childhood, have few cognitive or social problems decades following their diagnosis and treatment.
read press release 



Being Overweight Raises Risk of Men Developing Aggressive Prostate Cancer

(The Guardian [UK]) Nov 18, 2014 - World Cancer Research Fund review of global research finds link between obesity and advanced prostate cancer is strong.
read article 



Every Step You Take: STING Pathway Key to Tumor Immunity

(University of Chicago Medicine) Nov 20, 2014 - A recently discovered protein complex known as STING plays a crucial role in detecting the presence of tumor cells and promoting an aggressive anti-tumor response by the body's innate immune system, according to two separate studies published in the Nov. 20 issue of the journal Immunity.
read press release 



FDA Strengthens Warning on Device Linked to Cancer

(ABC News/Associated Press) Nov 24, 2014 - U.S. regulators have strengthened their warning against use of a once-popular device for gynecologic surgery that can spread unsuspected cancer, saying its risk is only justified in a fraction of patients.
read article 



Immuno-Oncology 2014 Press Release: High-Dose Interleukin-2 Effective in mRCC Pre-Treated With VEGF-Targeted Therapies

(ESMO) Nov 24, 2014 – High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.
read press release 



Private Oncologists Being Forced Out, Leaving Patients to Face Higher Bills

(New York Times) Nov 23, 2014 - Oncologists say they are being forced to sell or close their practices because insurers have reduced payments to them and because drugs are so expensive.
read article 



Amgen Stops Gastric-Cancer Drug Trials on Increase in Deaths

(Bloomberg) Nov 24, 2014 - Amgen Inc. ended clinical trials of a drug for advanced gastric cancer after an independent committee monitoring the studies found an increase in the number of deaths for people using the medicine along with chemotherapy.
read article 



Amgen Completes Singapore Plant

(San Fernando Valley Business Journal) Nov 20, 2014 - Amgen Inc. announced on Thursday the completion of its Next-Generation Biomanufacturing facility in Singapore, which it said would provide a model for future plants.
read article 



Novartis Wins European Backing For Psoriasis Drug Cosentyx

(Bloomberg) Nov 21, 2014 - Novartis AG won European backing for a treatment against psoriasis that will compete with Amgen Inc.’s Enbrel and may garner more than $1 billion in annual sales.
read article 



EMA Updates Conflict of Interest Policy

(PharmaTimes [UK]) Nov 20, 2014 - The European Medicines Agency has unveiled plans for updating its policy on potential conflicts of interest for scientific-committee members and experts, aiming for a more balanced, tailored and transparent approach from when it goes live in January next year.
read article 



F.D.A. Approves Hysingla, a Powerful Painkiller

(New York Times) Nov 20, 2014 - The Food and Drug Administration on Thursday approved a powerful long-acting opioid painkiller, alarming some addiction experts who fear that its widespread use may contribute to the rising tide of prescription drug overdoses.
read article 



Generic Drug Price Sticker Shock Prompts Probe by Congress

(ABC News) Nov 21, 2014 - The prices of some common generic drugs have skyrocketed in recent years, but the reasons remain murky, lawmakers said.
read article 



Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development

(NCCN) Nov 21, 2014 - NCCN has published the 20th annual edition of the NCCN Guidelines® for Prostate Cancer, one of the eight original NCCN Guidelines published in November 1996.
read press release 



MD Anderson, Memorial Hermann Deliver New Integrated Breast Screening and Diagnostic Programs

(MD Anderson) Nov 20, 2014 - Memorial Hermann and The University of Texas MD Anderson Cancer Center have launched operations under their recently formed partnership to offer high-quality, specialized breast screening and diagnostic services at a network of community breast care centers in the greater Houston area.
read press release 



CBO Puts Cost of “Doc Fix” Legislation at $144B Over 10 Years

(ACCC) Nov 20, 2014 - According to the latest estimate from the Congressional Budget Office (CBO), the cost of “doc fix” legislation to replace the sustainable growth rate (SGR) payment system would be $144 billion from 2015 to 2024.
read article 



Fighting Kids' Cancer, One Voucher at a Time

(CNBC) Nov 21, 2014 - Nancy Goodman's son Jacob was 8½ when he started getting debilitating headaches.
read article 



Examining the Rising Costs of Cancer Care

(WGGB-TV/ABC, Ch. 40 [Springfield, MA]) Nov 20, 2014 - It’s a grim reality and a dire decision facing thousands of cancer patients, even those with health insurance: the costs of treating cancer have skyrocketed and many sufferers can’t afford to stay alive.
read article 



Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

(TheStreet) Nov 21, 2014 – Biotech columnist Adam Feuerstein answers readers' questions about health care.
read article 



East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More

(Xconomy Boston) Nov 21, 2014 - One of the year’s biggest cancer meetings took place this week in Barcelona, and many biotechs from the East Coast were angling for the spotlight. Some wowed investors, others, not so much.
read article 



Immuno-Oncology 2014 Press Release: Immunotherapy Set to Revolutionise Cancer Treatment

(ESMO) Nov 20, 2014 – Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland (21-22 November).
read press release